CVRx, Inc. (CVRX)
CVRx, Inc. is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. Their flagship product, Barostim, is designed to improve symptoms for patients suffering from heart failure.
Company Overview
CVRx offers a novel neuromodulation therapy for heart failure patients, positioning it for growth in the cardiovascular device market. With a focus on Barostim, CVRx aims to improve patient outcomes and capture market share through direct sales and strategic partnerships.
Investment Thesis
CVRx presents a compelling investment opportunity due to its innovative Barostim therapy and its potential to address a significant unmet need in the heart failure market. The company's focus on neuromodulation offers a novel approach to managing heart failure symptoms, potentially leading to improved patient outcomes and reduced healthcare costs. With a gross margin of 85.0%, CVRx has a strong foundation for profitability as it scales its operations. Key growth catalysts include expanding market access, increasing physician adoption of Barostim, and demonstrating positive clinical outcomes. While the company currently operates at a loss with a profit margin of -92.9%, strategic execution and market penetration could drive significant revenue growth and improve profitability, making CVRx an attractive investment for those seeking exposure to innovative medical device technologies.
Key Highlights
- Market Cap of $0.17B indicates a small-cap company with potential for significant growth.
- Gross Margin of 85.0% demonstrates strong pricing power and efficient manufacturing processes.
- Beta of 1.28 suggests the stock is more volatile than the market, offering potential for higher returns but also higher risk.
- Focus on Barostim therapy provides a targeted approach to addressing heart failure, a large and growing market.
- International sales presence in Europe and other regions diversifies revenue streams and reduces reliance on the U.S. market.
Competitors
Strengths
- Innovative Barostim therapy addresses unmet need.
- High gross margin of 85.0%.
- Proprietary neuromodulation technology.
- Established sales and distribution network.
Weaknesses
- Negative profit margin of -92.9%.
- Limited market share compared to larger competitors.
- Reliance on a single product (Barostim).
- Requires significant investment in sales and marketing.
Catalysts
- Upcoming: Publication of new clinical data supporting Barostim's efficacy.
- Ongoing: Expansion of sales and marketing efforts in key markets.
- Upcoming: Securing reimbursement approvals in new geographies.
- Ongoing: Development of new applications for neuromodulation.
Risks
- Potential: Competition from established medical device companies.
- Ongoing: Reimbursement challenges from healthcare payers.
- Potential: Product liability claims related to Barostim.
- Ongoing: Dependence on the success of Barostim therapy.
Growth Opportunities
- Expanding Market Access: CVRx has the opportunity to expand its market access by securing reimbursement approvals in new geographies and expanding its sales force in existing markets. The global market for heart failure devices is estimated to reach billions of dollars, providing a significant runway for growth. By increasing its presence in key markets and securing favorable reimbursement policies, CVRx can drive adoption of Barostim and increase revenue.
- Increasing Physician Adoption: Driving increased physician adoption of Barostim is crucial for CVRx's growth. This can be achieved through targeted marketing campaigns, physician training programs, and the publication of positive clinical data. By educating physicians about the benefits of Barostim and providing them with the necessary training and support, CVRx can increase the number of patients who receive this therapy, leading to revenue growth.
- Demonstrating Positive Clinical Outcomes: Continued demonstration of positive clinical outcomes for Barostim is essential for driving adoption and securing reimbursement. By conducting clinical trials and publishing the results in peer-reviewed journals, CVRx can build confidence in the efficacy and safety of its therapy. Positive clinical data will also help to differentiate Barostim from competing therapies and strengthen CVRx's market position.
- Developing New Applications for Neuromodulation: CVRx has the opportunity to leverage its expertise in neuromodulation to develop new therapies for other cardiovascular diseases. This could involve adapting Barostim for use in different patient populations or developing entirely new neuromodulation devices. By expanding its product portfolio, CVRx can diversify its revenue streams and reduce its reliance on Barostim.
- Strategic Partnerships and Acquisitions: CVRx can accelerate its growth through strategic partnerships and acquisitions. This could involve partnering with other medical device companies to co-market Barostim or acquiring companies with complementary technologies or market access. Strategic partnerships and acquisitions can provide CVRx with access to new markets, technologies, and expertise, enabling it to grow more quickly and efficiently.
Opportunities
- Expanding market access through reimbursement approvals.
- Increasing physician adoption of Barostim.
- Developing new applications for neuromodulation.
- Strategic partnerships and acquisitions.
Threats
- Competition from established medical device companies.
- Reimbursement challenges from healthcare payers.
- Potential for product liability claims.
- Technological obsolescence.
Competitive Advantages
- Proprietary neuromodulation technology with patents.
- Clinical data supporting the efficacy of Barostim.
- Established relationships with key cardiologists.
- Specialized expertise in neuromodulation for heart failure.
About
CVRx, Inc., founded in 2000 and headquartered in Minneapolis, Minnesota, is a medical device company dedicated to developing, manufacturing, and commercializing innovative neuromodulation solutions for cardiovascular diseases. The company's primary focus is on addressing the unmet needs of patients with heart failure through its Barostim therapy. Barostim is a neuromodulation device specifically designed to improve symptoms in patients with heart failure with reduced ejection fraction, also known as systolic heart failure. This device utilizes neuromodulation to activate the body's natural cardiovascular control mechanisms, aiming to restore balance and improve overall heart function. CVRx sells its products through a combination of direct sales force and strategic partnerships with sales agents and independent distributors. The company's commercial reach extends across the United States, Germany, the rest of Europe, and select international markets. CVRx is committed to advancing the field of neuromodulation for cardiovascular health, striving to provide effective and innovative solutions that enhance the quality of life for patients with heart failure.
What They Do
- Develops neuromodulation solutions for cardiovascular diseases.
- Manufactures the Barostim device for heart failure patients.
- Commercializes Barostim therapy to improve heart function.
- Sells products through direct sales and distributors.
- Targets patients with heart failure with reduced ejection fraction.
- Provides a novel approach to managing heart failure symptoms.
Business Model
- Develops and manufactures the Barostim device.
- Sells Barostim directly to hospitals and clinics.
- Partners with distributors for wider market reach.
- Generates revenue through device sales and related services.
Industry Context
CVRx operates within the medical device industry, specifically targeting the cardiovascular market. The industry is characterized by continuous innovation and increasing demand for less invasive and more effective treatments for heart failure. The competitive landscape includes established medical device companies and emerging players focused on neuromodulation and other advanced therapies. CVRx's Barostim therapy offers a unique approach to heart failure management, positioning the company to capture a share of the growing market for cardiovascular devices. The company competes with companies like CERS, MASS, NNOX, OMI, and PRQR, all striving to innovate in the medical device space.
Key Customers
- Hospitals and clinics specializing in cardiology.
- Cardiologists and heart failure specialists.
- Patients with heart failure with reduced ejection fraction.
- Distributors of medical devices in the cardiovascular space.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $16M | -$12M | $-0.46 |
| Q3 2025 | $15M | -$13M | $-0.49 |
| Q2 2025 | $14M | -$15M | $-0.57 |
| Q1 2025 | $12M | -$14M | $-0.53 |
Source: Company filings
Chart & Info
Price Chart
CVRx, Inc. (CVRX) stock price: $7.67 (+0.57, +8.03%)
Why Bull
- •Recent insider buying suggests confidence in CVRx's growth potential, indicating that those closest to the company believe in its future.
- •Community sentiment has been increasingly positive, with discussions highlighting the innovative nature of CVRx's medical devices.
- •Analysts have noted the company's strong pipeline, which could lead to significant advancements in heart failure treatments.
- •Recent partnerships and collaborations in the healthcare sector have boosted optimism about CVRx's market position and product reach.
Why Bear
- •Some investors express concerns about the competitive landscape, fearing that larger companies may overshadow CVRx's innovations.
- •Recent earnings reports have shown slower growth than expected, leading to skepticism about the company's ability to scale effectively.
- •Market sentiment has been cautious, with discussions reflecting worries about regulatory challenges that could impact product launches.
- •There are apprehensions regarding the overall healthcare spending environment, which could affect CVRx's sales and revenue growth.
Latest News
-
Earnings Scheduled For February 12, 2026
benzinga · Feb 12, 2026
-
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires · Jan 23, 2026
-
Earnings Scheduled For November 5, 2025
benzinga · Nov 5, 2025
-
Earnings Scheduled For May 8, 2025
benzinga · May 8, 2025
Technical Analysis
Rationale
AI-generated technical analysis for CVRX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss CVRx, Inc. (CVRX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CVRX.
Make a Prediction
Set your price target for CVRx, Inc. (CVRX), choose a timeframe, and track your prediction accuracy.
Current price: $7.67
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CVRX.
Price Targets
Median: $11.50 (+49.9% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 10.4% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 10/100
Gross margin of 85.3% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 6/100
Adequate cash of $76M covers near-term needs but may require additional funding for aggressive expansion.
-
R&D Intensity 7/100
R&D at 19.7% of revenue shows meaningful innovation investment, typical of growth-oriented tech companies.
-
Insider Activity 3/100
Net insider selling of +$0.00M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 10/100
Daily turnover of 2.42% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CVRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does CVRx, Inc. do?
CVRx, Inc. is a medical device company focused on developing, manufacturing, and commercializing neuromodulation solutions for cardiovascular diseases. Its primary product, Barostim, is a device designed to improve symptoms in patients with heart failure with reduced ejection fraction. The company sells Barostim through a combination of direct sales and distribution partnerships in the United States, Europe, and other international markets. CVRx aims to provide innovative and effective therapies for patients with cardiovascular conditions, improving their quality of life and reducing the burden of heart failure.
Is CVRX stock a good buy?
CVRx stock presents a speculative investment opportunity with high potential reward but also significant risk. The company's innovative Barostim therapy addresses a large and growing market, and its high gross margin suggests strong pricing power. However, CVRx is currently unprofitable and faces competition from larger, more established medical device companies. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in CVRX, weighing the potential for growth against the challenges of profitability and market competition. Monitor key metrics like revenue growth, reimbursement approvals, and clinical trial results to assess the company's progress.
What are the main risks for CVRX?
CVRx faces several key risks, including competition from established medical device companies, reimbursement challenges from healthcare payers, and the potential for product liability claims. The company's reliance on a single product, Barostim, also poses a risk, as any issues with the device or its adoption could significantly impact revenue. Additionally, CVRx's current unprofitability and negative profit margin of -92.9% raise concerns about its ability to achieve sustainable profitability. Investors should carefully consider these risks before investing in CVRX and monitor the company's progress in addressing these challenges.
Is CVRX a good stock to buy?
Whether CVRX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the CVRX MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is CVRX data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for CVRX?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to CVRx, Inc..
Who are CVRX's main competitors?
CVRx, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how CVRX compares.
What do analysts say about CVRX?
Analyst ratings and price targets for CVRX are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is CVRX's market cap?
Market capitalization reflects the total market value of CVRX's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has CVRX stock performed recently?
Check the Chart & Info tab for CVRX's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in CVRX?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for CVRX-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling CVRX?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for CVRX.
Is CVRX a good stock for beginners?
CVRx, Inc. (CVRX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CVRX for first-time investors?
Every stock carries risk, including CVRx, Inc. (CVRX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CVRX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.